ian_scott_final001019.jpg
360.348.7712


Education
Ph.D. Synthetic Chemistry, University of Sheffield, England, 1989
M.Phil. Synthetic Chemistry, University of Sheffield, England, 1987
B.Sc. (Hons) Chemistry, University of Sheffield, England, 1985
Postdoctoral Fellow w/ Dr. Marie Krafft, Florida State University, 1989-1992
CHEMICAL DEVELOPMENT
dr.i.l.scott@gmail.com
Site Updated 11/11/14
News
3.03.14
The Wall Street Journal: "Acucela Completes Enrollment in the Emixustat Hydrochloride Phase 2b/3 Clinical Trial"
7.3.14
Medscape: "FDA Approves Belinostat for Rare Lymphoma"
ian_scott_final001015.jpg
Recently Issued:
US 8,450,527: (May 28, 2013)
Scott, Ian Leslie; Kuksa, Vladimir Aleksandrovich; Orme, Mark W.; Hong, Feng; Little, Thomas; Gall, Anna; Gage, Jennifer.
VLA-4 antagonist for the treatment of asthma and MS.
                    LICENSED to Encysive and Schering-Plough
Novel tubulin inhibitor for the treatment of solid tumors.
                    LICENSED in 2012 to Bessor-Brightwaters Pharma
PRINCIPAL INVENTOR
ian_scott_final001010.jpg
Now in Phase 2b/3 clinical trials.
US 8,492,589: (July 23, 2013)
Scott, Ian L.; Kuksa, Vladimir A.; Orme, Mark W.; Kubota, R.
US 8,674,137: (March 18, 2014)
Scott, Ian L.; Kuksa, Vladimir A.; Orme, Mark W.; Hong, Feng; Little, Thomas L.; Kubota, R.
US 8,653,142: (February 18, 2014)
Scott, Ian L.; Kuksa, Vladimir A.; Orme, Mark W.; Hong, Feng; Little, Thomas L.; Kubota, R.
US 8,716,529: (May 6, 2014)
Scott, Ian Leslie; Kuksa, Vladimir Aleksandrovich; Orme, Mark W.; Little, Thomas; Gall, Anna; Gage, Jennifer; Hong, Feng.
ian_scott_final001009.gif
For dry AMD. "Exmixustat is the first agent in a class of novel compounds...designed specifically to target enzymes of the visual cycle." Retinal Physician, 5/1/13
          LICENSED: Cash/milestones, $263 million; Otsuka (2008, Partial rights)
               

      



TBC-4746


     

    ALB-109564(a)


       
          Emixustat HCl
            (ACU-4429)
AMRI
A C U C E L A
S P E C T R U M
ALLERGAN
Pharmaceuticals
US 8,766,007: (July 1, 2014)
Scott, Ian Leslie; Kuksa, Vladimir Aleksandrovich; Orme, Mark W.; Little, Thomas; Gall, Anna; Gage, Jennifer; Hong, Feng.

Vinca with tubulin

Beleodaq (Belinostat) + 16 additional clinical candidates

                            
Author of CMC regulatory documents:
                                    
IND
ANDA
sNDA

Author of API Section; Beleodaq NDA filing
(approved July 3, 2014)

US 8,829,244: (September 9, 2014)
Scott, Ian Leslie; Kuksa, Vladimir Aleksandrovich; Orme, Mark W.; Little, Thomas; Gall, Anna; Gage, Jennifer; Hong, Feng.